Elusys Overview
- Year Founded
-
1998
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
PE Growth
- Financing Rounds
-
11
Elusys General Information
Description
Developer of antibody therapeutics designed to treat life-threatening infectious diseases. The company's therapeutics treat anthrax exposure following a natural or intentional release of anthrax spores and also treat biodefense, cancer, lupus nephritis, contagious diseases, and thrombosis, enabling patients to prevent inhaled anthrax.
Contact Information
Website
www.elusys.comCorporate Office
- 4 Century Drive
- Suite 260
- Parsippany, NJ 07054
- United States
Corporate Office
- 4 Century Drive
- Suite 260
- Parsippany, NJ 07054
- United States
Elusys Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Elusys Comparisons
Industry
Financing
Details
Elusys Competitors (2)
One of Elusys’s 2 competitors is Atea Pharmaceuticals, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Atea Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Aridis Pharmaceuticals | Formerly VC-backed | Los Gatos, CA |
Elusys Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Elusys Patents
Elusys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2008140487-A2 | Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use | Inactive | 14-Nov-2006 | ||
| WO-2008140487-A3 | Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use | Inactive | 14-Nov-2006 | ||
| US-20090010928-A1 | Anti-anthrax antibody, formulations thereof, and methods of use | Active | 28-Sep-2006 | ||
| US-20120156196-A1 | Anti-anthrax antibody, formulations thereof, and methods of use | Active | 28-Sep-2006 | ||
| WO-2008042261-A2 | Anti-anthrax antibody, formulations thereof, and methods of use | Inactive | 28-Sep-2006 | C07K16/1278 |
Elusys Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Elusys Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Elusys FAQs
-
When was Elusys founded?
Elusys was founded in 1998.
-
Where is Elusys headquartered?
Elusys is headquartered in Parsippany, NJ.
-
What is the size of Elusys?
Elusys has 27 total employees.
-
What industry is Elusys in?
Elusys’s primary industry is Biotechnology.
-
Is Elusys a private or public company?
Elusys is a Private company.
-
What is Elusys’s current revenue?
The current revenue for Elusys is .
-
How much funding has Elusys raised over time?
Elusys has raised $56.1M.
-
Who are Elusys’s investors?
LEONID has invested in Elusys.
-
Who are Elusys’s competitors?
Atea Pharmaceuticals and Aridis Pharmaceuticals are competitors of Elusys.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
